Literature DB >> 12175095

Severe hypocholesterolemia with reduced serum lipoprotein(a) in a patient with visceral leishmaniasis.

Evagellos Liberopoulos1, George Alexandridis, Eleni Bairaktari, Moses Elisaf.   

Abstract

We report the case of a 36-yr-old man with visceral leishmaniasis who presented with marked hypocholesterolemia, mild hypertriglyceridemia, severely decreased serum levels of HDL-cholesterol, LDL-cholesterol, apolipoproteins AI and B, and increased serum level of apolipoprotein E. Moreover, serum Lp(a) level was markedly reduced on presentation, which is the first published report on Lp(a) levels in kala-azar. Possible mechanisms for the observed alterations of the serum lipid profile are discussed.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12175095

Source DB:  PubMed          Journal:  Ann Clin Lab Sci        ISSN： 0091-7370            Impact factor:   1.256


  11 in total

1.  Canine visceral leishmaniosis: the relationship of blood serum thyroid hormones, lipids, and lipoproteins with clinical status.

Authors:  M Khaleghi Einakchi; N Sedaghat Sharifi; J Khoshnegah; M Heidarpour
Journal:  Parasitol Res       Date:  2018-09-27       Impact factor: 2.289

Review 2.  Lipid testing in infectious diseases: possible role in diagnosis and prognosis.

Authors:  Sebastian Filippas-Ntekouan; Evangelos Liberopoulos; Moses Elisaf
Journal:  Infection       Date:  2017-05-08       Impact factor: 3.553

3.  Hypertriglyceridemia: a possible diagnostic marker of disease severity in visceral leishmaniasis.

Authors:  C S Lal; R B Verma; N Verma; N A Siddiqui; V N Rabidas; K Pandey; D Singh; S Kumar; R K Paswan; A Kumari; P Sinha; P Das
Journal:  Infection       Date:  2015-07-10       Impact factor: 3.553

4.  Association between Hypertriglyceridemia and Disease Severity in Visceral Leishmaniasis.

Authors:  Mariana Garcez Varela; Mariana de Oliveira Bezerra; Felipe Vieira Santana; Marcos Couto Gomes; Pedro Ribeiro de Jesus Almeida; Geydson Silveira da Cruz; Enaldo Vieira de Melo; Paulo Roberto de Oliveira Costa; Fabrícia Alvisi de Oliveira; Amélia Ribeiro de Jesus; Roque Pacheco de Almeida
Journal:  Am J Trop Med Hyg       Date:  2021-11-22       Impact factor: 2.345

5.  Persistence of an atherogenic lipid profile after treatment of acute infection with Brucella.

Authors:  F Apostolou; I F Gazi; A Kostoula; C C Tellis; A D Tselepis; M Elisaf; E N Liberopoulos
Journal:  J Lipid Res       Date:  2009-06-17       Impact factor: 5.922

6.  Alteration of Clinical Chemistry Parameters Among Visceral Leishmaniasis Patients in Western Tigrai, Ethiopia, 2018/2019: A Comparative Cross-Sectional Study.

Authors:  Brhane Tesfanchal; Gebremedhin Gebremichail; Getachew Belay; Gebreslassie Gebremariam; Gebreyohannes Teklehaimanot; Hagos Haileslasie; Getachew Kahsu; Aderajew Gebrewahd; Fitsum Mardu; Gebre Adhanom; Brhane Berhe; Hirut Teame; Aster Tsegaye; Mistire Wolde
Journal:  Infect Drug Resist       Date:  2020-08-26       Impact factor: 4.003

7.  Hypolipidemia: a word of caution.

Authors:  Rr Elmehdawi
Journal:  Libyan J Med       Date:  2008-06-01       Impact factor: 1.657

8.  Host cholesterol influences the activity of sterol biosynthesis inhibitors in Leishmania amazonensis.

Authors:  Valter Viana Andrade-Neto; Pedro Paulo de Abreu Manso; Miria Gomes Pereira; Nuccia Nicole Theodoro de Cicco; Georgia Corrêa Atella; Marcelo Pelajo-Machado; Rubem Figueiredo Sadok Menna-Barreto; Eduardo Caio Torres-Santos
Journal:  Mem Inst Oswaldo Cruz       Date:  2022-04-04       Impact factor: 2.743

9.  Lipid derangement as diagnostic and prognostic indicator for visceral leishmaniasis patients.

Authors:  Sarita Mohapatra; Jyotish C Samantaray; Saroj Dash; Laxshmi Ramakrishan
Journal:  Trop Parasitol       Date:  2014-07

10.  Leishmania donovani targets Dicer1 to downregulate miR-122, lower serum cholesterol, and facilitate murine liver infection.

Authors:  June Ghosh; Mainak Bose; Syamal Roy; Suvendra N Bhattacharyya
Journal:  Cell Host Microbe       Date:  2013-03-13       Impact factor: 21.023
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.